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Abstract
Background: The neuroprotective effects of duloxetine, as 
an antidepressant agent, and the neurodegenerative effects 
of methamphetamine have been shown in previous studies. 
Nonetheless, their exact neurochemical and behavioral 
effects are still unclear. In the current study, we sought to 
clarify the molecular mechanisms involved in the protective 
effects of duloxetine against methamphetamine-induced 
neurodegeneration.
Methods: Forty adult male rats were divided randomly into 
5 groups. Group 1 was the negative control and received 
normal saline, Group 2 was the positive control and received 
methamphetamine, and Groups 3, 4, and 5 were concurrently 
treated with methamphetamine (10 mg/kg) and duloxetine 
(5, 10, and 15 mg/kg, respectively). All the treatments were 
continued for 21 days. Between days 17 and 21, the Morris Water 
Maze (MWM) was used to assess learning and memory in the 
treated groups. On day 22, the hippocampus was isolated from 
each rat and oxidative, antioxidant, and inflammatory factors 
were measured. Additionally, the expression levels of the total 
and phosphorylated forms of the Akt and GSK3 proteins were 
evaluated via the ELISA method.
Results: Duloxetine in all the administered doses ameliorated the 
effects of the methamphetamine-induced cognition impairment 
in the MWM. The chronic abuse of methamphetamine increased 
malondialdehyde, tumor necrosis factor-α, and interleukin-1β, 
while it decreased superoxide dismutase, glutathione peroxidase, 
and glutathione reductase activities. Duloxetine not only prevented 
these malicious effects of methamphetamine but also activated 
the expression of Akt (both forms) and inhibited the expression of 
GSK3 (both forms) in the methamphetamine-treated rats.
Conclusion: We conclude that the Akt/GSK3 signaling pathways 
might have a critical role in the protective effects of duloxetine 
against methamphetamine-induced neurodegeneration and 
cognition impairment.
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Original Article
What’s Known
• Methamphetamine abuse can 
cause neurodegenerative disorders and 
neurobehavioral changes. Protective 
properties of duloxetine against 
neurobehavioral and neurodegenerative 
disorders were reported by previous 
investigations.
What’s New
• Current study indicated the protective 
role of duloxetine in the amelioration 
of methamphetamine-induced anxiety, 
depression, motor activity disturbance, 
and cognition impairment.
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Introduction
Duloxetine is an antidepressant of serotonin–
norepinephrine reuptake inhibitors (SNRIs) and 
is used to treat depression and anxiety and 
to enhance cognition.1,2 Some recent studies 
have revealed that this agent, because of its 
effects on the reuptake of both serotonin and 
norepinephrine, can be effective as a sedative 
and anxiolytic agent.1,2 These studies have 
suggested that since duloxetine has both 
anxiolytic and antidepressant effects, it can 
be used to treat the abuse of amphetamine 
and other psychostimulants and to modulate 
the cognitive and neurodegenerative effects 
of methamphetamine abuse.1,2 Further, 
this agent has neuroprotective and anti-
inflammatory effects and can act against some 
neurodegenerative situations such as ischemia.3 
Duloxetine can also be effective in the treatment 
of the abuse of other drugs such as alcohol.4,5 
The neuroprotective effects of duloxetine and 
its role in the inhibition of oxidative stress, 
inflammation, and apoptosis have been reported 
in several investigations; the exact molecular 
mechanisms of these effects, however, have 
hitherto remained ambiguous.3, 6
Methamphetamine is a neurostimulant with 
an increased rate of abuse in recent years.7 
The mechanisms of the biochemical and 
behavioral consequences of the chronic abuse 
of methamphetamine are still far from clear 
in adults and children.8-11 The mechanism of 
methamphetamine action is to increase the 
release of dopamine, norepinephrine, and to a 
lesser extent serotonin into synaptic terminals, 
causing the hyperstimulation of receptors in the 
acute phase and the downregulation of receptors 
in the chronic phase.8-11 Methamphetamine 
functionally and pharmacologically is similar to 
cocaine and this similarity creates a high potential 
for abuse and addiction.7 The chronic abuse of 
methamphetamine and also its withdrawal can 
induce behavioral changes such as cognition 
(learning and memory) impairment in human and 
experimental models.8-11 Experimental studies 
have confirmed the potential of methamphetamine 
in inducing neurodegeneration in some areas 
of the brain such as the hippocampus, which is 
responsible for cognition impairment.9 Research 
has also confirmed methamphetamine-induced 
oxidative stress, inflammation, and apoptosis 
in brain areas such as the hippocampus; 
nevertheless, what has thus far remained unclear 
is the molecular aspects and the signaling 
pathways involved.12, 13
Many previous investigations have indicated 
that phosphatidylinositol 3-kinase can activate 
protein kinase B (Akt) in brain cells. This 
activation inhibits glycogen synthase kinase 3 
(GSK3), which is involved in neurodegeneration, 
and protects cells from its neurodegenerative 
effects.14,15 Earlier research has also 
demonstrated the role of the Akt/GSK3 signaling 
pathways in cognitive activity.14
Because of the importance of the Akt/
GSK3 signaling pathways in the modulation of 
neuroprotection and cognition performance, we 
designed the present study to assess the role of 
these pathways in conferring the neuroprotective 
effects of duloxetine against methamphetamine-
induced neurodegeneration and alterations in 
cognitive activities. We hope that the results of the 
current study will confer a better understanding of 
amphetamine toxicity and the mechanisms involved.
Materials and Methods
Animals: Forty adult male Wistar rats, weighing 
between 250 and 300 g, were obtained from 
the Animal House of Iran University of Medical 
Sciences. They were kept under a controlled 
temperature (22±0.5 °C) with 12-hour light/
dark cycles and had free access to food and 
water. Our experiments were undertaken in Iran 
University of Medical Sciences (Tehran, Iran) 
in 2017, and our experimental protocol, which 
adhered to the guidelines on animal ethics and 
welfare, was approved by the Ethics Committee 
of Iran University of Medical Sciences.16
Drugs: Methamphetamine and duloxetine 
were purchased from Sigma-Aldrich Co. (St. 
Louis, Missouri, USA), and they were freshly 
prepared just before use. Methamphetamine was 
dissolved in normal saline, and duloxetine was 
dissolved in warmed normal saline. The exact 
doses of methamphetamine and duloxetine 
were calculated based on the animals’ weight; 
these amounts were dissolved in 0.2 mL/rat as 
the volume of injection for each rat.
Experimental design: Group 1, the negative 
control, was administrated with normal saline 
(0.2 mL/rat, i.p.) for 21 days and Group 2, the 
positive control, received methamphetamine 
(10 mg/kg, i.p., 0.2 mL/rat) for 21 days. 
Groups 3, 4, and 5 were treated concurrently with 
methamphetamine (10 mg/kg, i.p., 0.2 mL/rat) and 
duloxetine (5, 10, and 15 mg/kg, i.p., 0.2 mL/rat) 
respectively, for 21 days.
Between days 17 and 21, the Morris Water Maze 
(MWM) was used to evaluate learning and spatial 
memory in all the treated animals. The effects of 
duloxetine against methamphetamine-induced 
neurodegeneration and the role of the Akt/GSK3 
signaling pathways were studied by anesthetizing 
all the rats on day 22 through the administration of 
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50 mg/kg of thiopental. Afterward, the animals’ brain 
tissues were removed and the hippocampus was 
isolated from each rat according to the guidelines 
presented in previous studies.17 The hippocampus 
from the right hemisphere was used for the evaluation 
of oxidative stress and inflammation biomarkers, 
whereas the left hemisphere’s hippocampus was 
used for the evaluation of the expression of the Akt 
and GSK3 proteins.
Behavioral Studies
MWM task: The MWM, as the standard 
behavioral test for the evaluation of cognition 
and spatial memory, was performed based on 
previous studies.18 This test evaluates the time 
of escape latency (characterized by time to find 
a hidden platform), traveled distance (measured 
as the distance each animal covers to reach 
the hidden platform), and percentage of the 
presence of the animals in the target quarter.18
Molecular Study
Determination of oxidative stress parameters: 
The levels of lipid peroxidation, malondialdehyde 
(MDA) production, interleukin-1β (IL-1β), and 
tumor necrosis factor-α (TNF-α) as well as 
the activities of superoxide dismutase (SOD), 
glutathione peroxidase (GPx), and glutathione 
reductase (GR) were measured as described 
previously by standard protocols.19, 20
Measurement of the expression of the 
proteins: The immunoreactivity of Akt (total 
and phosphorylated) and GSK3 (total and 
phosphorylated) was studied in the isolated 
hippocampus using an ELISA commercial kit 
(MyBioSource, San Diego, USA) according to 
previous studies.14, 21
Statistical Analysis
The data were analyzed using GraphPad 
PRISM, version 6 (2016). First, the normality 
of the continuous variables (behavioral and 
molecular parameters) was assessed using the 
Kolmogorov–Smirnov test. Based on this test, all 
the variables were normally distributed. All the 
data were described as means±standard errors 
of the mean (SEMs), and the differences between 
the treatment groups were evaluated using one-
way ANOVA with the Bonferroni posttest for 
group-by-group comparisons. The results were 
considered significant at a P level less than 0.05.
Results
Duloxetine Improved Spatial Memory in 
Methamphetamine-Induced Cognition Impairment
The parameters of escape latency and 
traveled distance were increased during 4 days 
of training in the MWM for the groups under 
treatment with methamphetamine (10 mg/kg); 
the difference with the negative control group 
constituted statistical significance (P≤0.001 for 
escape latency and P=0.007 for the traveled 
distance) (figures 1 and 2). The swimming 
speed was not altered during the training trials 
in the control and methamphetamine-treated 
groups (P=0.95) (figure 3). Moreover, the 
presence (%) in the target quarter was reduced 
among the animals receiving methamphetamine 
(10 mg/kg) (P≤0.001) (figure 4). Duloxetine 
in all the administered doses ameliorated the 
methamphetamine-induced reduction in escape 
latency (P≤0.001) and the percentage of the 
presence of the animals in the target quarter 
Figure 1: Average of escape latency in the negative 
control group, the group under treatment with 10 mg/kg 
of methamphetamine (positive control), and the groups 
under treatment with methamphetamine in combination 
with duloxetine (5, 10, and 15 mg/kg) across all the training 
days using the Morris Water Maze (MWM) in the rats. All 
the data are expressed as means±SEMs (n=8). METH: 
Methamphetamine; DUL: Duloxetine; *Shows the level 
of significance (P≤0.001) in comparison to the negative 
control group. #Shows the level of significance (P≤0.001) 
in comparison to the positive control group (10 mg/kg of 
methamphetamine).
Figure 2: Traveled distance in the negative control group, the 
group under treatment with 10 mg/kg of methamphetamine 
(positive control), and the groups under treatment with 
methamphetamine in combination with duloxetine (5, 10, 
and 15 mg/kg) across all the training days using the Morris 
Water Maze (MWM) in the rats. All the data are expressed 
as means±SEMs (n=8). METH: Methamphetamine; DUL: 
Duloxetine; *Shows the level of significance (P=0.007) 
in comparison to the negative control group. #Shows the 
level of significance (P=0.007) in comparison to the positive 
control group (10 mg/kg of methamphetamine).
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(P≤0.001) and increased the traveled distance 
(P=0.007) as compared to the methamphetamine 
(10 mg/kg)-treated groups (figures 1, 2, and 4). 
The swimming speed was not altered during the 
training trials in the methamphetamine-treated 
groups in comparison with the duloxetine-treated 




significantly increased lipid peroxidation as 
indicated by elevated mitochondrial MDA 
levels. It also decreased the activities of 
SOD, GPx, and GR when compared to the 
negative control (P≤0.001 for MDA, P=0.013 
for SOD, P=0.025 for GPx, and P=0.024 for 
GR) (table 1). Conversely, the various doses of 
duloxetine (5, 10, and 15 mg/kg) reduced the 
methamphetamine-induced rise in the MDA level 
and ameliorated the methamphetamine-induced 
decrease in SOD, GPx, and GR activities when 
compared to the positive controls (P≤0.001 for 
MDA, P=0.013 for SOD, P=0.025 for GPx, and 
P=0.024 for GR) (table 1).
Duloxetine Prevented a Methamphetamine-
Induced Rise in Inflammatory Biomarkers
The animals in the methamphetamine-treated 
groups demonstrated significant elevations 
in IL-1β and TNF-α levels as compared to the 
negative control group (P=0.008 for IL-1β and 
P≤0.001 for TNF-α) (table 1). Conversely, the 
high doses of duloxetine (10 and 15 mg/kg) 
prevented a methamphetamine-induced rise in 
pro-inflammatory biomarkers when compared 
to the positive controls (P=0.008 for IL-1β and 
P≤0.001 for TNF-α) (table 1).
Duloxetine Inhibited Methamphetamine-Induced 
Alterations in the Expressions of Both Forms of 
the Akt and GSK3 Proteins
Methamphetamine (10 mg/kg) treatment 
markedly reduced the relative protein expression/
level of Akt (total and phosphorylated) and 
GSK3 (total and phosphorylated) in the rats’ 
hippocampus in comparison to the negative 
control group (P=0.009 for total Akt, P=0.008 
for phosphorylated Akt, P≤0.001 for total 
GSK3, and P=0.002 for phosphorylated GSK3) 
(figures 5, 6, 7, and 8). Conversely, the high 
doses of duloxetine (10 and 15 mg/kg) treatment 
significantly improved the protein expression/
level of Akt (total and phosphorylated) and 
GSK3 (total and phosphorylated) in the 
methamphetamine-treated animals when 
compared to the methamphetamine-only-
treated group (P=0.009 for total Akt, P=0.008 for 
phosphorylated Akt, P≤0.001 for total GSK3, and 
P=0.002 for phosphorylated GSK3) (figures 5, 6, 
7, and 8).
Discussion
The current study demonstrated that multiple 
doses of duloxetine were able to modulate 
the methamphetamine-induced oxidative 
stress, inflammation, and cognition (learning 
and memory) impairment. According to our 
findings, duloxetine modulated the Akt/GSK3 
signaling pathways and thus ameliorated the 
behavioral and molecular changes induced by 
methamphetamine administration.
Methamphetamine is a neural stimulant with 
an increasing abuse rate among youngsters, 
due to its similarity to cocaine, in recent 
Figure 3: Swimming speed in the negative control group, the 
group under treatment with 10 mg/kg of methamphetamine 
(positive control), and the groups under treatment with 
methamphetamine in combination with duloxetine (5, 10, 
and 15 mg/kg) across all the training days using the Morris 
Water Maze (MWM) in the rats. All the data are expressed 
as means±SEMs (n=8). METH: Methamphetamine; DUL: 
Duloxetine;
Figure 4: Percentages of the time spent in the target 
quarter in the probe trial in the negative control group, the 
group under treatment with 10 mg/kg of methamphetamine 
(positive control), and the groups under treatment with 
methamphetamine in combination with duloxetine (5, 10, 
and 15 mg/kg) across all the training days using the Morris 
Water Maze (MWM) in the rats. All the data are expressed 
as means±SEMs (n=8). METH: Methamphetamine; DUL: 
Duloxetine; *Shows the level of significance (P≤0.001) 
in comparison to the negative control group. #Shows the 
level of significance (P≤0.001) in comparison to the positive 
control group (10 mg/kg of methamphetamine).
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Table 1: Effects of the various doses of duloxetine on the alterations of oxidative stress and inflammatory biomarkers in the 

















Control 6.1±0.9 66.2±4.1 71.2±6.2 51.1±4.1 56.4±6.1 50.3±4.2
Meth (10mg/kg) 20.4±1.4a 30.3±3.1a 36.2±6.4a 22.1±3.2 100.5±8.6a 92.6±8.1a
Meth (10mg/kg) + Duloxetine
(5 mg/kg)
13±1.6b 45.4±5.2b 49.3±7.1b 33.2±5.1b 90.5±5.9a 88.1±9.1a
Meth (10mg/kg) + Duloxetine
(10 mg/kg)
11±2b 51.4±4.3b 59.1±5.2b 41.1±5.2b 68.5±6.5b 64.6±2.9b
Meth (10 mg/kg) + 
Duloxetine (15 mg/kg)
10±2.1b 58.2±5.4b 66.2±6.1b 48.4±4.1b 60.5±5.5b 61.8±2.2b
ashows the level of significance with P≤0.001(MDA level), P=0.013 (for SOD), P=0.025 (for GPx), P=0.024 (for GR), 
P=0.008 (for IL-1β), and P≤0.001 (for TNF-α ) vs. the negative control groups; bshows the level of significance with 
P≤0.001(MDA level), P=0.013 (for SOD), P=0.025 (for GPx), P=0.024 (for GR), P=0.008 (for IL-1β), and P≤0.001 (for 
TNF-α) vs. the positive control group (methamphetamine only). MDA: Malondialdehyde; SOD: Superoxide dismutase; 
GPx: Glutathione peroxidase; TNF-α: Tumor necrosis factor-α; IL-1β: Interleukin-1β; Meth: Methamphetamine
Figure 5: Alterations in the expression/level (ELISA) 
of Akt (total form) in the hippocampus in the negative 
control group, the group under treatment with 10 mg/kg of 
methamphetamine (positive control), and the groups under 
treatment with methamphetamine in combination with 
duloxetine (5, 10, and 15 mg/kg). All the data are expressed 
as means±SEMs (n=8). METH: Methamphetamine; DUL: 
Duloxetine; *Shows the level of significance (P=0.009) 
in comparison to the negative control group. #Shows the 
level of significance (P=0.009) in comparison to the positive 
control group (10 mg/kg of methamphetamine).
Figure 6: Alterations in the expression/level (ELISA) of Akt 
(phosphorylated form) in the hippocampus in the negative 
control group, the group under treatment with 10 mg/kg of 
methamphetamine (positive control), and the groups under 
treatment with methamphetamine in combination with 
duloxetine (5, 10, and 15 mg/kg). All the data are expressed 
as means±SEMs (n=8). METH: Methamphetamine; DUL: 
Duloxetine; *Shows the level of significance (P=0.008) 
in comparison to the negative control group. #Shows the 
level of significance (P=0.008) in comparison to the positive 
control group (10 mg/kg of methamphetamine).
Figure 7: Alterations in the expression/level (ELISA) of 
GSK3 (total form) in the hippocampus in the negative 
control group, the group under treatment with 10 mg/kg of 
methamphetamine (positive control), and the groups under 
treatment with methamphetamine in combination with 
duloxetine (5, 10, and 15 mg/kg). All the data are expressed 
as means±SEMs (n=8). METH: Methamphetamine; DUL: 
Duloxetine; *Shows the level of significance (P≤0.001) 
in comparison to the negative control group. #Shows the 
level of significance (P≤0.001) in comparison to the positive 
control group (10 mg/kg of methamphetamine).
Figure 8: Alterations in the expression/level (ELISA) of GSK 
(phosphorylated form) in the hippocampus in the negative 
control group, the group under treatment with 10 mg/kg of 
methamphetamine (positive control), and the groups under 
treatment with methamphetamine in combination with 
duloxetine (5, 10, and 15 mg/kg). All the data are expressed 
as means±SEMs (n=8). METH: Methamphetamine; DUL: 
Duloxetine; *Shows the level of significance (P=0.002) 
in comparison to the negative control group. #Shows the 
level of significance (P=0.002) in comparison to the positive 
control group (10 mg/kg of methamphetamine).
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years.8, 22 Methamphetamine augments the 
release of dopamine and norepinephrine into 
the synaptic cleft, but the neurobehavioral 
and neurochemical consequences of its 
chronic abuse remain unclear.22 Duloxetine 
is an SNRI antidepressant used primarily for 
the treatment of depression, general anxiety 
disorder, social phobia, panic disorder, and 
vasomotor symptoms.23,24 Duloxetine can be 
effective in the treatment of neurobehavioral 
and neurochemical disorders related to various 
drug abuse and their withdrawal syndromes; 
be that as it may, its exact mechanism has 
hitherto remained uncertain.2,22 We found that 
the chronic administration of methamphetamine 
at a dose of 10 mg/kg increased escape latency 
and the traveled distance in the MWM in terms 
of learning time. Additionally, methamphetamine 
administration (10 mg/kg) decreased learning 
activity and also on the probe test day, it 
lessened the percentage of the presence of the 
animals in the target quarter in the MWM, which 
is associated with malicious effects on memory 
performance. These data suggest that the long-
term administration of methamphetamine can 
attenuate spatial memory in rodents and also 
confirm the results of the previous investigations 
having reported that the chronic administration 
of methamphetamine or the withdrawal of this 
neurostimulant reduces cognitive function in 
rats.25-27 Methamphetamine-like compounds 
lead to the release of dopamine, serotonin, 
and noradrenaline in the brain, triggering the 
downregulation of the mentioned neurotransmitter 
receptors. The consequence of this phenomenon 
is cognition impairment during the abuse or 
withdrawal of this agent.25-27 According to our 
results, duloxetine at all the administered 
doses was able to alter the methamphetamine-
induced learning and memory impairment. Many 
previous studies have indicated that SNRIs 
such as duloxetine have significant effects on 
learning and memory and can exert positive 
effects on cognitive activity.6,22,28 In our molecular 
findings, methamphetamine (10 mg/kg) altered 
oxidative stress and neuroinflammation. We 
observed that whereas methamphetamine 
decreased SOD, GPx, and GR activities, it 
increased the MDA level (a marker of lipid 
peroxidation) in the rat hippocampus. Previous 
studies have indicated that the chronic 
administration of methamphetamine begets 
mitochondrial dysfunction and alteration in 
respiratory chain enzymes in the brain cells of 
rodents. These studies have suggested that 
methamphetamine can induce oxidative stress 
in the brain of rats.29,30 Nevertheless, the exact 
mechanism of the action of methamphetamine 
in this regard still remains undetermined.30 
The results of the current study chime in with 
those of the previous studies having reported 
methamphetamine-induced lipid peroxidation 
in brain cells.31,32 Some novel reports have 
shown that methamphetamine consumption 
inhibits antioxidant activity in multiple cells, and 
these effects create methamphetamine-induced 
degenerative impacts on body cells such as 
those in the brain, liver, and heart.32 Previous 
studies have reported that methamphetamine 
abuse diminishes antioxidant defense, which 
may result in neurodegeneration.31,32 In 
accordance with previous studies, treatment by 
duloxetine in the current study was found to be 
effective in reversing this methamphetamine-
induced increase in the MDA level and reversing 
the reduction in SOD, GPx, and GR activities 
in the hippocampal tissues.3,33,34 The role of 
SNRIs such as duloxetine in the activation of 
antioxidant defense and the increase in the 
activities of antioxidant enzymes has been 
previously reported by multiple studies.34,35 
All of these investigations have reported that 
duloxetine and other similar compounds can 
activate mitochondrial antioxidant enzymes 
and by this type of activation can be involved in 
neuroprotection against some neurotoxic agents 
such as morphine and amphetamine- type 
stimulants.34,35 Our results demonstrated that the 
inflammatory biomarkers in the hippocampus 
were increased by methamphetamine 
administration at a dose of 10 mg/kg. Previous 
similar studies have indicated that the 
chronic administration of methamphetamine 
increases pro-inflammatory markers such as 
TNF-α and IL-1β, which is consistent with our 
findings, although the signaling mechanism 
of these effects has yet to be elucidated.31 
Furthermore, we found that duloxetine inhibited 
methamphetamine-induced inflammation; this 
finding is concordant with previous studies.34,35 
The anti-inflammatory role of duloxetine 
and other antidepressants has been shown 
already, and this property is the reason for its 
effectiveness in autoimmune disorders34,35 and 
neuroprotective effects against neurotoxic agent-
induced inflammation.4, 34, 35 As was noted above, 
duloxetine ameliorated the methamphetamine-
induced cognition impairment, oxidative stress, 
and inflammation in the hippocampal cells of 
our rats; this finding to some extent confirms the 
results of previous studies on the neuroprotective 
effects of duloxetine.4, 34, 35 Nonetheless, to define 
the mechanism of its neuroprotective action, 
we sought to evaluate the molecular basis and 
the possible signaling pathways involved in 
cognitive activity and neurodevelopment. Thus, 
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we evaluated the Akt/GSK3 signaling pathways 
and found that methamphetamine decreased 
the Akt protein level/expression in both total 
and phosphorylated forms, while it increased 
GSK3 in both forms. These data are in line 
with the previous investigations having shown 
that methamphetamine-type stimulants inhibit 
the phosphorylation of Akt in brain cells and 
that this inhibition of Akt leads to the activation 
and phosphorylation of GSK3.36 According to 
the present data, by the activation of GSK3, 
some neurodegenerative events will occur in 
brain cells and some neurobehavioral disorders 
such as cognition impairment can be related 
to the inhibition of Akt and the activation of 
GSK3, involved in neurodegeneration.15 In 
the present study, duloxetine ameliorated the 
methamphetamine-induced decrease in the 
Akt protein level/expression in both total and 
phosphorylated forms, while it decreased 
GSK3 in both forms in the methamphetamine-
treated rats.33, 37 It has been shown by many 
previous studies that antidepressant effects 
against neurodegeneration are mediated by the 
modulation of the Akt/GSK3 and other similar 
signaling pathways.15, 33, 37 However, the role of 
Akt/GSK3 in neurobehavioral and neurochemical 
changes induced by duloxetine has yet to be fully 
clarified. According to our findings, duloxetine 
and other similar agents might act through these 
pathways (Akt/GSK3) and rescue cell survival 
and trigger neuroprotection. These novel results 
give us new insights into the molecular effects of 
duloxetine in hippocampal cells.
Conclusion
In light of the results of the present study, we 
can conclude that the chronic administration 
of methamphetamine in adult rats causes 
disturbances in learning and spatial memory 
and can trigger the activation of oxidative 
stress and inflammation. According to our 
data, the inhibition of Akt, which causes the 
activation of GSK3, might be responsible for 
this type of neurodegeneration. In addition, 
our data indicated that duloxetine could act 
against methamphetamine-induced cognition 
impairment and neurodegeneration. It is worthy 
of note that, for the first time, the current study 
showed that the Akt/GSK3 signaling pathways 
might be involved in the protective effects of 
duloxetine against methamphetamine-induced 
neurobehavioral and biochemical malicious 
effects. Although these findings confer a new 
insight into the hitherto unknown mechanisms of 
methamphetamine-induced neurodegeneration, 
further evaluation of the precise molecular and 
cellular aspects of the protective properties of 
duloxetine against methamphetamine-induced 
neurodegeneration and cognition impairment 
seems necessary.
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